Personalized mRNA Vaccine Shows Promise for Aggressive Triple-Negative Breast Cancer
In Mexico, breast cancer remains the most prevalent cancer among women. In 2022, the National Institute of Statistics and Geography reported 23,790 new cases diagnosed in women aged 20 and over. A particularly challenging subtype, triple-negative breast cancer, affects between 10 and 15% of all diagnoses and disproportionately impacts younger women. Researchers at Houston Methodist Hospital are developing a personalized messenger RNA (mRNA) vaccine aimed at revolutionizing treatment for this aggressive form of the disease.
Understanding Triple-Negative Breast Cancer
Triple-negative breast cancer is defined by the absence of three key receptors – estrogen receptor, progesterone receptor, and HER2 – typically used to guide treatment. Dr. Kai Sun, breast oncologist and assistant professor at Houston Methodist, explains that without these targets, “It is not possible to apply hormonal or targeted therapies, so chemotherapy remains the basis of treatment.” Despite advancements in chemotherapy, the prognosis for triple-negative breast cancer is often less favorable than other breast cancer types.
Harnessing the Immune System with a Personalized Vaccine
Dr. Sun’s team focused on triple-negative breast cancer due to its unique biological characteristic: it is more immunogenic, meaning the immune system is more likely to recognize it. The goal is to leverage this natural ability by stimulating the immune system with a personalized vaccine that trains the body to defend itself against cancer.
How the Study Works
The study focuses on women with early-stage triple-negative breast cancer who, after undergoing chemotherapy before surgery, still have residual tumor. These patients face a high risk of relapse within the first five years. The project aims to identify specific DNA changes within each tumor and design a vaccine that trains the immune system to target those mutations and eliminate any remaining cancer cells.
This process involves a multidisciplinary team at Houston Methodist Hospital utilizing cutting-edge technology. Collaboration includes the mRNA Department led by Dr. Cooke, infectious disease specialist Dr. Gollihar who analyzes genetic sequences, and Dr. Taraballi’s group, responsible for encapsulating the vaccine in nanoparticles for administration. From tumor sequencing to the first vaccine dose, the entire process takes six to eight weeks. Dr. Sun acknowledges, “It is an enormous technical and logistical challenge,” emphasizing the need for precision, coordination, and resources to administer the vaccine before surgery.
Early Results and Future Directions
Currently in phase 1, the project is focused on confirming safety and determining the most effective dosage. Researchers aim to identify the amount that elicits the best immune response with minimal risk. The goal is to improve disease-free survival rates. Dr. Sun notes that the three-year risk of recurrence in this patient group is around 50%, but the vaccine aims to increase disease-free survival to 70%.
The technological platform shows promise for application to other cancers. “There is already encouraging data in melanoma and pancreatic cancer,” says Dr. Sun. If safety and efficacy are demonstrated, the vaccine could be adapted to combat other aggressive cancers.
A New Era in Cancer Treatment
Dr. Sun believes this work marks the beginning of a new era in cancer treatment. He anticipates that within the next five to ten years, these vaccines could be approved and available for patients with early-stage cancer, representing a significant shift towards not only treating the disease but also preventing its return. He concludes, “We are living in an exciting time in cancer research. This vaccine represents a real opportunity to improve the lives of patients. It is not just about science, it is about giving them a new possibility.”